肝組織内HBc抗原の局所によるインターフェロン投与効果の判定

概要

論文の詳細を見る
HBeAg-positive 18 patients with chronic acitve hepatitis were treated with MR-21 (Interferon-β, Mochida). In relation to antiviral effects using DNA-polymerase and HBeAg (EIA) in sera, the change of HBcAg after treatment was quantitatively evaluated, by immunoperoxidase method, in liver biopsy specimens taken from all patients within 4 weeks before the treatment and also after the treatment. A marked depression of HBcAg was shown in liver of 8 patients after the treatment, but intrahepatic HBcAg was still demonstrated in 7 of 10 patients whose DNA-polymerase disappeared in their sera. In 12 patients with many HBcAg-positive heaptocytes, the intrahepatocytic expression of HBcAg showed nuclear and cytoplasmic pattern in 6 cases and mostly cytoplasmic pattern in 5 cases. The latter group showed low titer of DNA-P and HBeAg (EIA) in sera as compared with the former group, and also the latter one often demonstrated a depression of HBcAg in liver after the treatment.
社団法人日本肝臓学会の論文